Fig. 2: ERK1/2 mutations are relatively rare.
From: ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
In July 2023, the query of 69223 samples belonging to 65853 patients in 213 curated and non-redundant studies in cBiportal for only mutations among conventional effectors of the ERKp yielded the approximate frequencies as displayed. Note that this oversimplified schematic is not meant to communicate complex signaling and structures of the effectors. Unlike typical oncogenes, ERK1/2 mutations are distributed along the ERK protein’s conserved protein kinase and non-conserved regions, with no hotspot mutational site. Figure generated in Biorender.
